Phrutsamon Wongnak

Phrutsamon Wongnak

Auto-generated profile, based on publicly available information

Phrutsamon Wongnak

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2024 in Peer Community Journal
Verified
Journal Article
Closed access
PDF file
THThierry Hoch
Thierry Hoch
AMAurélien Madouasse
Aurélien Madouasse
MJMaude Jacquot
Maude Jacquot
PWPhrutsamon Wongnak
Phrutsamon Wongnak
FREDERIC BEUGNETFREDERIC BEUGNET
FREDERIC BEUGNET
AAAlbert Agoulon
Albert Agoulon
There is growing concern about climate change and its impact on human health. Specifically, global warming could increase the probability of emerging infectious diseases, notably because of changes in the geographical and seasonal distributions of disease vectors such as mosquitoes and ticks. For example, the range of Ixodes ricinus , the most common and widespread tick species in Europe, is currently expanding northward and at higher altitudes. However, little is known about the seasonal variation in tick abundance in different climates. Seasonality of I. ricinus is often based on expert opinions while field surveys are usually limited in time. Our objective was to describe seasonal variations in I. ricinus abundance under different climates. To this end, a seven-year longitudinal study, with monthly collections of I. ricinus host-seeking nymphs, was carried out in France, in six locations corresponding to different climates. Tick data were log-transformed and grouped between years so as to obtain seasonal variations for a typical year. Daily average temperature was measured during the study period. Seasonal patterns of nymph abundance were established for the six different locations using linear harmonic regression. Model parameters were estimated separately for each location. Seasonal patterns appeared different depending on the climate considered. Western temperate sites showed an early spring peak, a summer minimum and a moderate autumn and winter abundance. More continental sites showed a later peak in spring, and a minimum in winter. The peak occurred in summer for the mountainous site, with an absence of ticks in winter. In all cases except the mountainous site, the timing of the spring peak could be related to the sum of degree days since the beginning of the year. Winter abundance was positively correlated to the corresponding temperature. Our results highlight clear patterns in the different sites corresponding to different climates, which allow further forecast of tick seasonality under changing climate conditions.

21 August 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PWPhrutsamon Wongnak
Phrutsamon Wongnak
JWJames A Watson
James A Watson
PJPodjanee Jittamala
Podjanee Jittamala
WSWilliam H K Schilling
William H K Schilling
TSTimothy Seers
Timothy Seers
NWNicholas J White
Nicholas J White

27 July 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
THThierry Hoch
Thierry Hoch
AMAurélien Madouasse
Aurélien Madouasse
MJMaude Jacquot
Maude Jacquot
PWPhrutsamon Wongnak
Phrutsamon Wongnak
FREDERIC BEUGNETFREDERIC BEUGNET
FREDERIC BEUGNET
AAAlbert Agoulon
Albert Agoulon
There is growing concern about climate change and its impact on human health. Specifically, global warming could increase the probability of emerging infectious diseases, notably because of changes in the geographical and seasonal distributions of disease vectors such as mosquitoes and ticks. For example, the range of Ixodes ricinus , the most common and widespread tick species in Europe, is currently expanding northward and at higher altitudes. However, little is known about the seasonal variation in tick abundance in different climates. Seasonality of I. ricinus is often based on expert opinions while field surveys are usually limited in time. Our objective was to describe seasonal variations in I. ricinus abundance under different climates. To this end, a seven-year longitudinal study, with monthly collections of I. ricinus host-seeking nymphs, was carried out in France, in six locations corresponding to different climates. Tick data were log-transformed and grouped between years so as to obtain seasonal variations for a typical year. Daily average temperature was measured during the study period. Seasonal patterns of nymph abundance were established for the six different locations using linear harmonic regression. Model parameters were estimated separately for each location. Seasonal patterns appeared different depending on the climate considered. Western temperate sites showed an early spring peak, a summer minimum and a moderate autumn and winter abundance. More continental sites showed a later peak in spring, and a minimum in winter. The peak occurred in summer for the mountainous site, with an absence of ticks in winter. In all cases except the mountainous site, the timing of the spring peak could be related to the sum of degree days since the beginning of the year. Winter abundance was positively correlated to the corresponding temperature. Our results highlight clear patterns in the different sites corresponding to different climates, which allow further forecast of tick seasonality under changing climate conditions.

30 April 2026 in Philosophical Transactions of the Royal Society B: Biological Sciences
Verified
Journal Article
Open access
PWPhrutsamon Wongnak
Phrutsamon Wongnak
TSTim Seers
Tim Seers
PJPodjanee Jittamala
Podjanee Jittamala
MIMallika Imwong
Mallika Imwong
WSWilliam Schilling
William Schilling
NWNicholas J. White
Nicholas J. White
Pharmacometric assessment of antiviral efficacy in acute influenza informs treatment decisions and pandemic preparedness. We characterized natural viral clearance in acute influenza to guide phase II trial design using simulations based upon observed data. Standardized duplicate oropharyngeal swabs were collected daily over 14 days from 80 untreated low-risk Thai adults, with viral densities measured using quantitative polymerase chain reaction. We evaluated three models to describe viral clearance: exponential, bi-exponential and growth-and-decay. The growth-and-decay model provided the best fit, but the exponential decay model was the most parsimonious. The median viral clearance half-life was 10.3 h (interquartile range (IQR): 6.8–15.4h), varying by influenza type: 9.6 h (IQR: 6.2–13.0 h) for influenza A and 14.0 h (IQR: 10.3–19.3 h) for influenza B. Simulated trials using parameters from the exponential decay model showed that 148 patients per arm provide over 90% power to detect treatments accelerating viral clearance by 40%. Variation in clearance rates strongly impacted the power; doubling this variation would require 232 patients per arm for an antiviral with a 60% effect size. A sampling strategy with four swabs per day reduces the required sample size to 81 per arm while maintaining over 80% power. We recommend this approach to assess and compare current anti-influenza drugs. This article is part of the Theo Murphy meeting issue ‘Evaluating anti-infective drugs’.

17 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
PWPhrutsamon Wongnak
Phrutsamon Wongnak
WSWilliam Hk Schilling
William Hk Schilling
PJPodjanee Jittamala
Podjanee Jittamala
SBSimon Boyd
Simon Boyd
Viravarn LuviraViravarn Luvira
Viravarn Luvira
TGthe PLATCOV Collaborative Group
the PLATCOV Collaborative Group
Background: Effective antiviral drugs prevent hospitalisation and death in COVID-19. Antiviral efficacy can be assessed efficiently in-vivo by measuring rates of SARS-CoV-2 clearance estimated from serial viral genome densities quantitated in nasopharyngeal or oropharyngeal swab eluates. We carried out an individual patient data meta-analysis of unblinded arms in the PLATCOV platform trial to characterise changes in viral clearance kinetics and infer optimal design and interpretation of antiviral pharmacometric evaluations. PLATCOV is registered at ClinicalTrials.gov, NCT05041907 . Methods: Serial viral density data were analysed from symptomatic, previously healthy, adult patients (within 4 days of symptom onset) enrolled in a large multicentre randomised adaptive pharmacodynamic platform trial (PLATCOV) comparing antiviral interventions for SARS-CoV-2. Viral clearance rates over one week were estimated under a hierarchical Bayesian linear model with B-splines used to characterise temporal changes in enrolment viral densities and clearance rates. Bootstrap re-sampling was used to assess the optimal duration of follow-up for pharmacometric assessment, where optimal is defined as maximising the expected z-score when comparing effective antivirals with no treatment. Results: Between 29 September 2021 and 20 October 2023, 1262 patients were randomised. Unblinded data were available from 800 patients (16,818 oropharyngeal viral qPCR measurements) of whom 63% (504/800) were female. 98% (783/800) had received at least one vaccine dose and over 88% (703/800) were fully vaccinated. SARS-CoV-2 viral clearance was biphasic (bi-exponential). The first phase ( α ) was accelerated by effective interventions. For all the effective interventions studied, maximum discriminative power (maximum expected z-score) was obtained when evaluating serial data from the first 5 days after enrolment. Over the two-year period studied, median viral clearance half-lives estimated over 7 days have shortened from 16.6 hours (interquartile range [IQR]: 15.3 to 18.2) in September 2021 to 9.2 hours (IQR: 8.0 to 10.6) in October 2023 in patients receiving no antiviral drugs, equivalent to a relative reduction of 44% [95% credible interval (CrI): 19 to 64%]. A parallel trend was observed in treated patients. In the 158 patients randomised to ritonavir-boosted nirmatrelvir (3,380 qPCR measurements), the median viral clearance half-life declined from 6.4 hours (IQR: 5.7 to 7.3) in June 2022 to 4.8 hours (IQR: 4.2 to 5.5) in October 2023, a relative reduction of 26% [95%CrI: –4 to 42%]. Conclusions: SARS-CoV-2 viral clearance kinetics in symptomatic vaccinated individuals have accelerated substantially over the past two years. Antiviral efficacy in COVID-19 can now be assessed efficiently in-vivo using serial qPCRs from duplicate oropharyngeal swab eluates taken daily for 5 days after drug administration. Funding: Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.

12 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
PWPhrutsamon Wongnak
Phrutsamon Wongnak
TSTim Seers
Tim Seers
PJPodjanee Jittamala
Podjanee Jittamala
MIMallika Imwong
Mallika Imwong
WSWilliam Hk Schilling
William Hk Schilling
NWNicholas J White
Nicholas J White
Pharmacometric assessment of antiviral efficacy in acute influenza informs treatment decisions and pandemic preparedness. We characterised natural viral clearance in acute influenza to guide phase II trial design using simulations based upon observed data. Standardized duplicate oropharyngeal swabs were collected daily over 14 days from 80 untreated low-risk Thai adults, with viral densities measured using qPCR. We evaluated three models to describe viral clearance: exponential, bi-exponential, and growth-and-decay. The growth-and-decay model provided the best fit, but the exponential decay model was the most parsimonious. The median viral clearance half-life was 10.3 hours (interquartile range [IQR]: 6.8–15.4), varying by influenza type: 9.6 hours (IQR: 6.2–13.0) for influenza A and 14.0 (IQR: 10.3–19.3) hours for influenza B. Simulated trials using parameters from the exponential decay model, showed that 148 patients per arm provide over 90% power to detect treatments accelerating viral clearance by 40%. Variation in clearance rates strongly impacted the power; doubling this variation would require 232 patients per arm for an antiviral with a 60% effect size. A sampling strategy with four swabs per day reduces the required sample size to 81 per arm while maintaining over 80% power. We recommend this approach to assess and compare current anti-influenza drugs.